Ofatumumab in the treatment of multiple sclerosis – from clinical outcomes to the economic sustainability of treatment

Česká verze

Authors: S. Halúsková ¹; M. Vališ ²; Z. Pavelek ³
Authors place of work: Neurologická klinika FZS Univerzity Pardubice a Nemocnice Pardubického kraje, Pardubice ¹; Research Institute for Biomedical Science – Výzkumný ústav biomedicínských věd, z. ú., Hradec Králové ²; Neurologická klinika LF UK a FN Hradec Králové ³
Published in the journal: Cesk Slov Neurol N 2026; 89(1): 9-15
Category: Přehledný referát
doi: https://doi.org/10.48095/cccsnn20269

Summary

The importance of early initiation of therapy for the long-term prognosis of patients with relapsing-remitting MS is supported by evidence from open-label extension studies as well as real-world clinical data, both consistently demonstrating an association between early intervention and a slower disability progression. Given the growing number of available disease-modifying drugs and the substantial socioeconomic burden associated with MS, it is essential to identify not only cost-effective pharmaceutical agents, but also optimal therapeutic strategies that take into account both clinical efficacy and long-term sustainability within the healthcare system. Ofatumumab fulfills the criteria of a modern 21^st-century drug and represents a therapy with dual benefits –⁠ for both the patient and the healthcare system.

Keywords:

costs – Multiple sclerosis – Pharmacoeconomics – ofatumumab – high-effi cacy therapy

Zdroje

1. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018; 31 (6): 752–759. doi: 10.1097/WCO.0000000000000622.

2. Česká správa sociálního zabezpečení. Vyplácené invalidní důchody dle jednotlivých diagnóz 2024. [online]. Dostupné z: https: //www.cssz.cz/duchodova-statistika#section_4.

3. Kobelt G, Berg J, Lindgren P et al. Costs and quality of life of multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006; 7 (Suppl 2): S5–S13. doi: 10.1007/s10198-006-0365-y.

4. Blahova Dusankova J, Kalincik T, Dolezal T et al. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler J 2012; 18 (5): 662–668. doi: 10.1177/13524 58511424422.

5. Simoens S. Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Front Neurol 2022; 13 : 1015256. doi: 10.3389/fneur.2022.1015256.

6. Rai M, Goyal R. Pharmacoeconomics in healthcare. In: Vohora D, Singh G (eds). Pharmaceutical medicine and translational clinical research. 1st ed. Amsterdam: Academic Press 2018 : 465–472.

7. Doležal T. Význam farmakoekonomického hodnocení. In: Kolektiv autorů (eds). Základy farmakoekonomiky pro lékaře, lékárníky a další pracovníky ve zdravotnictví. Praha: Česká farmako-ekonomická společnost 2007 : 9–13.

8. Karampampa K, Gustavsson A, Miltenburger C et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012; 18 (2 Suppl): 7–15. doi: 10.1177/135245 8512441566.

9. Hawton A, Goodwin E, Boddy K et al. Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years. Mult Scler 2022; 28 (3): 346–351. doi: 10.1177/1352458520 954172.

10. NICE –⁠ NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Technology appraisal guidance: multiple sclerosis. [online]. Available from: https: //nice.org.uk.

11. ICER –⁠ INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW. Disease-modifying therapies for multiple sclerosis: evidence report. [online]. Available from: https: //icer.org.

12. Havrdova E, Kobelt G, Berg J et al. New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic. Mult Scler J 2017; 23 (2_suppl): 41–52. doi: 10.1177/1352458517708117.

13. Maresova P, Valis M, Novotny M et al. The direct costs of multiple sclerosis –⁠ study in the Czech Republic. Neurol Sci 2018; 39 (12): 2115–2121. doi: 10.1007/s10072-018-3551-7.

14. Všeobecná zdravotní pojišťovna. Šest z deseti pacientů s roztroušenou sklerózou má biologickou léčbu. Jde o třetí nejrychleji rostoucí diagnostickou skupinu. [online]. Dostupné z: https: //www.vzp.cz/o-nas/aktuality/sest-z-deseti-pacientu-s-roztrousenou-sklerozou-ma-biologickou-lecbu-jde-o-treti-nejrychleji-rostouci-diagnostickou-skupinu.

15. Vališ M, Halúsková S. Ofatumumab: state of the art 2024 –⁠ Kde jsme nyní a kam směřujeme. Cesk Slov Neurol N 2024; 87/120 (5): 313–316. doi: 10.48095/ cccsnn2024313.

16. Buron MD, Chalmer TA, Sellebjerg F et al. Initial high--efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. Neurology 2020; 95 (8): e1041–e1051. doi: 10.1212/WNL.0000000000010135.

17. He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020; 19 (4): 307–316. doi: 10.1016/S1474-4422 (20) 30067-3.

18. Schmierer K, Sørensen PS, Baker D. Highly effective disease-modifying treatment as initial MS therapy. Curr Opin Neurol 2021; 34 (3): 286–294. doi: 10.1097/WCO. 0000000000000937.

19. Hauser SL, Fox E, Aungst A et al. Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis. Neurology 2022; 98 (18_supplement): 2517. doi: 10.1212/WNL.98.18_supplement.251.

20. Pipek LZ, Mahler JV, Vidigal Nascimento RF et al. Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 2023; 71 : 104581. doi: 10.1016/j.msard.2023.104581.

21. Smets I, Versteegh M, Huygens S et al. Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model. Mult Scler J Exp Transl Clin 2023; 9 (3): 20552173231189398. doi: 10.1177/20552173231189398.

22. Abulhasanbeigi Gallehzan N, Khosravi M, Jamebozorgi K et al. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review. Health Econ Rev 2024; 14 (1): 12. doi: 10.1186/s13561-024-00478-7.

23. Patwardhan MB, Matchar DB, Samsa GP et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005; 11 (2): 232–239. doi: 10.1191/1352458505ms1137oa.

24. NOVARTIS. New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients. [online]. Available from: https: //www.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients.

25. Pardo G, Bar-Or A, Montalban X et al. Continuous ofatumumab treatment up to 7 years shows a consistent safety profile and delays disability progression in people with relapsing multiple sclerosis [abstract]. Neurology 2025; 104 (7_Supplement_1): P7-1.016. doi: 10.1212/WNL.0000000000210474.

26. Vudumula U, Patidar M, Gudala K et al. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain. J Med Econ 2023; 26 (1): 11–18. doi: 10.1080/13696998.2022.2151270.

27. Baharnoori M, Bhan V, Clift F et al. Cost-effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Pharmacoecon Open 2022; 6 (6): 859–870. doi: 10.1007/ s41669-022-00363-1.

28. Koeditz D, Frensch J, Bierbaum M et al. Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: a cost-consequence analysis from a societal perspective in Germany. Mult Scler J Exp Transl Clin 2022; 8 (1): 20552173221085741. doi: 10.1177/20552173221 085741.

29. Bhan V, Clift F, Baharnouri M et al. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res 2023; 12 (9): e220175. doi: 10.57264/cer-2022-0175.

30. Inshasi J, Nowier Y, Zimovetz EA et al. Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates. Ther Adv Neurol Disord 2025; 18 : 17562864251330260. doi: 10.1177/17562864251330260.

31. Pracovní skupina pro tvorbu doporučených postupů ČFES. Doporučené postupy České farmakoekonomické společnosti (ČFES) pro zdravotně-ekonomická hodnocení v ČR. [online]. Dostupné z: https: //farmakoekonomika.cz/wp-content/uploads/2016/10/ Doporučené-postupy_final.pdf.